We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topics
- Shortages and supply disruptions (21)
- Safety monitoring and information (13)
- Manufacturing (7)
- Compliance and enforcement (6)
- Labelling and packaging (4)
- Import and export (3)
- Scheduling (national classification system) (3)
- Committees and advisory bodies (2)
- Legislation (2)
- Advertising (1)
- Clinical trials (1)
- Fees and payments (1)
- Medicinal cannabis hub (1)
Collection content
113 result(s) found, displaying 31 to 40
-
GuidanceGuidance on the mandatory requirements for reporting current and anticipated reportable medicine shortages and discontinuations in Australia.
-
GuidanceGuidance about application pathways and data requirements for new generic medicines, and variations to existing medicines.
-
GuidanceGuidance to understand the quality requirements of Therapeutic Goods Order No. 101 - Standard for tablets, capsules and pills (TGO 101, the Order).
-
GuidanceGuidance for sponsors about how to apply for orphan drug designation for a prescription medicine.
-
GuidanceGuidance on submitting the CPD for prescription medicines.
-
GuidanceGuidance on specific criteria and paperwork required for submission to the TGA to ensure conformance with TGO 93.
-
GuidanceGuidance on how to prepare your application for orphan drug designation so that it meets eligibility criteria and requirements.
-
PageEvaluation plan estimators to approximate dates of milestones in the prescription medicine registration process.
-
GuidanceGuidance on applying for a provisional determination, which is the first step of the provisional approval pathway.
-
GuidanceGuidance on how to request early scientific advice on a biowaiver justification.